December 1, 2022 – Renal & Urology News (By: Natasha Persaud) Veterans with cardiovascular disease or diabetes have slightly longer survival when treated with enzalutamide vs abiraterone for metastatic castration-resistant prostate cancer (mCRPC), a new study finds. In a retrospective study of 5822 veterans treated for mCRPC during 2014-2017, 43% initially received enzalutamide, an androgen…
Read More-We now offer focal therapy for prostate cancer, using cryotherapy (CRYO) and high-intensity focused ultrasound (HIFU). With the addition of this these techniques, Tulane Urology is now THE comprehensive and most experienced treatment site in this region for the management of ALL stages of prostate cancer. From early diagnosis where active surveillance is recommended, to…
Read More
It would appear that a new treatment that is effective in heavily pre-treated patients may be on the near-term horizon. Dr. Sartor is the lead author of a New England Journal of Medicine (NEJM) article published June 23, 2021 that demonstrates that PSMA-617 Lu-177 prolongs survival in patients with metastatic prostate cancer. These patients had undergone multiple…
Read More